The Benefits of Instant-Release Color-Coating Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Benefits of Instant-Release Color-Coating Systems
The author discusses a new fillm-coating system to create customized colors and the research an development tools used in conjunction with this system. This article is part of a special supplement on Excipients and Solid Dosage.


Pharmaceutical Technology
Issue 34, pp. s20-s22


COURTESY OF THE AUTHOR
Developing a film-coating color for an oral, solid-dose pharmaceutical product comes with some challenges. Creating and choosing the color for an instant-release coating for a new product not only involves working with associates across several areas such as research and development, manufacturing, and marketing, but also often includes the manual process of formulating individual coatings to evaluate color options. Automating the process of developing and evaluating a color formulation helps to save time and reduce costs when developing an oral solid dosage product. This article examines currently applied manual color systems and a new automated color system using excipient technology and specialized software tools.

Manual color systems

The manual film-coating color-development process can be difficult and time-consuming. Developing a film-coating color involves the selection and formulation of the optimal ratio of polymer to plasticizer to achieve a successful coating. The process of determining the correct pigments, pigment concentrations, and pigment combinations needed to reach a desired color can be tedious. Pigment selection is further complicated by taking into consideration the colorants needed to reach a final color and how the regulatory status of each colorant affects acceptability in different regions of the world. This situation is often the case with iron oxides and aluminum lakes.

Once a film-coating color formulation has been finalized, the process of making the formulation for use in production has to be considered and developed. This process often involves preparing a suspension by adding separately each of the individual ingredients, which include polymers, plasticizers, and pigments. Depending on the film-coating ingredients, as with hypromellose, for example, this process can be time-consuming. In addition, specific colorants may need to be individually processed before use, for example, by reducing the particle size of ingredients, to optimize performance. Colorant testing to ensure that the final film-coating color is consistent from batch to batch adds further complexity.

Immediate-release film coatings


Figure 1 (FIGURES 1 AND 2 ARE COURTESY OF THE AUTHOR)
To simplify this process, BASF (Ludwigshafen, Germany) created a new fully formulated color-coating system for immediate release film-coatings using a polyvinyl alcohol polymer grafted onto polyethylene glycol in a ratio of approximately 75:25 (Kollicoat IR). The coatings are manufactured using seven base colors and are fully formulated using globally accepted pigments (i.e., those in accordance with: the US Code of Federal Regulation, Title 21, "Food and Drugs"; the BIRYO limits on trace amounts as specified by Japan's Ministry of Health, Labor and Welfare; and the Dictionary of Pharmaceutical Excipients (Japan)) in combination with a manufacturing process that results in coating granules that are easy to use. Examples of each of the seven base colors are provided in Figure 1.


Figure 2
As described in Figure 2, each pigment is brought into suspension together with polymers to form seven base color preparations. These preparations form solid dispersions of pigments in the polymer. The free-flowing, nearly dust-free granules, are readily dispersible in water and can be easily combined to create color options. The basic components are combined onsite to form the desired color. A coating system of the desired color is produced, and the coating system is readily dispersible to form the coating suspension.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here